Szalat Lab

Publications

Papers, meeting abstracts, and posters co-authored by Raphael E. Szalat, newest first. Current lab members are shown in bold.

Papers 69

2026

  1. Cyclin D1 immunostaining as a diagnostic surrogate for the t(11;14) translocation in AL amyloidosis

    George T, Staron A, Burks EJ, Szalat RE, Sanchorawala V

    British Journal of Haematology208(6):2252-2255DOIPubMed

  2. Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma

    Aktas Samur A, Corre J, Talluri S, …, Szalat R, …, Samur MK

    Journal of Clinical Oncology44(4):321-334DOIPubMed

  3. Hepatic response criteria in light chain amyloidosis: a multicenter validation study

    Muchtar E, Palladini G, Schonland S, …, Szalat R, …, Gertz MA

    HaematologicaDOIPubMed

  4. Tailoring Therapy for Frail and Elderly Myeloma Patients

    George T, Szalat RE

    The Cancer Journal32(5)DOIPubMed

  5. When ICAN(S) Becomes ICAN’T: Clinician and Staff Perspectives on In-Hospital Neurotoxicity Grading

    Ferri GM, Frank A, Li D, …, Szalat RE, …, Bell BN

    Clinical Lymphoma Myeloma and Leukemia26(1):e77-e82DOIPubMed

2025

  1. Bleeding Patterns and Clinical Outcomes in Patients With Systemic AL Amyloidosis‐Related Acquired Factor X Deficiency

    Cetin O, Staron A, Teodorescu P, Sloan JM, Sanchorawala V, Szalat R

    American Journal of Hematology100(12):2416-2420DOIPubMed

  2. Exploring the effect of Duffy status on patients with breast cancer receiving cyclin-dependent kinase 4/6 inhibitors

    Ferri GM, Martinez CB, Acevedo J, …, Szalat RE, Sloan JM

    Breast Cancer Research and Treatment215(1)DOIPubMed

  3. ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3

    Fulciniti M, Yao Y, Perini T, …, Szalat R, …, Munshi NC

    Blood Cancer Discovery7(1):129-141DOIPubMed

  4. Implementing geriatric assessments using the practical geriatric assessment in older adults being evaluated for cellular therapies at a safety-net hospital

    Abdallah M, Fogale A, Halpin M, Szalat R, Fantasia K

    Journal of Geriatric Oncology16(8):102667DOI

  5. Neighborhood disadvantage and multiple myeloma incidence in the Black Women’s Health Study

    Holder EX, Szalat R, Palmer JR, Bertrand KA

    International Journal of Epidemiology54(6)DOIPubMed

  6. Teclistamab therapy for refractory type 1 cryoglobulinemia

    Battaglini J, Henderson J, Sanchorawala V, Szalat R

    Haematologica110(8):1891-1893DOIPubMed

2024

  1. Body size and risk of multiple myeloma in the Black Women’s Health Study

    Kataria Y, Pillalamarri BN, Zirpoli G, Szalat R, Palmer JR, Bertrand KA

    British Journal of Cancer130(5):830-835DOIPubMed

  2. Bone marrow stromal cells induce chromatin remodeling in multiple myeloma cells leading to transcriptional changes

    Binder M, Szalat RE, Talluri S, Fulciniti M, Avet-Loiseau H, Parmigiani G, Samur MK, Munshi NC

    Nature Communications15(1)DOIPubMed

  3. Deciphering racial disparities in multiple myeloma outcomes

    Bertrand KA, Szalat R

    Blood Advances8(1):234-235DOIPubMed

  4. Febrile neutropenia in patients with Duffy-null–associated neutrophil counts and multiple myeloma or AL amyloidosis

    Abdallah M, Arters F, Patel J, …, Szalat R

    Blood Advances8(23):5935-5938DOIPubMed

  5. Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain Amyloidosis

    Muchtar E, Wisniowski B, Geyer S, …, Szalat R, …, Gertz MA

    JAMA Oncology10(10):1362DOIPubMed

  6. Role of minimal residual disease assessment in multiple myeloma

    Szalat R, Anderson K, Munshi N

    Haematologica109(7):2049-2059DOIPubMed

2023

  1. Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis

    Muchtar E, Dispenzieri A, Wisniowski B, …, Szalat R, …, Gertz MA

    Journal of Clinical Oncology41(7):1393-1403DOIPubMed

  2. High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma

    Samur MK, Roncador M, Aktas Samur A, …, Szalat R, …, Munshi NC

    Blood141(14):1724-1736DOIPubMed

  3. Single-Cell Profiling in Multiple Myeloma: Insights, Problems, and Promises

    Samur MK, Szalat R, Munshi NC

    BloodDOIPubMed

2022

  1. Light chain amyloidosis associated with Waldenström macroglobulinemia: treatment and survival outcomes

    Gustine JN, Szalat RE, Staron A, Joshi T, Mendelson L, Sloan JM, Sanchorawala V

    Haematologica108(6):1680-1684DOIPubMed

  2. Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25‐year longitudinal study

    Gustine JN, Staron A, Szalat RE, …, Sanchorawala V

    American Journal of Hematology97(9):1189-1199DOIPubMed

  3. Prevalence of monoclonal gammopathy of undetermined significance in US black women

    Bertrand KA, Zirpoli G, Pillalamarri BN, Szalat R, Palmer JR, Kataria Y

    American Journal of Hematology97(9)DOIPubMed

  4. Recent common human coronavirus infection protects against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: A Veterans Affairs cohort study

    Fillmore NR, Szalat RE, La J, …, Munshi NC

    Proceedings of the National Academy of Sciences119(46)DOIPubMed

2021

  1. Clinical Characteristics, Treatment Regimens, and Survival in Elderly Patients with AL Amyloidosis

    Acevedo J, Doros G, Szalat R, Sanchorawala V

    Clinical Lymphoma Myeloma and Leukemia21(6):425-426DOIPubMed

  2. Genetic Predictors of Mortality in Patients with Multiple Myeloma

    Hassan H, Szalat R

    The Application of Clinical GeneticsVolume 14:241-254DOIPubMed

  3. IgM-MM is predominantly a pre–germinal center disorder and has a distinct genomic and transcriptomic signature from WM

    Bazarbachi AH, Avet-Loiseau H, Szalat R, …, Samur MK

    Blood138(20):1980-1985DOIPubMed

  4. Lack of differential impact of del17p on survival in African Americans compared with White patients with multiple myeloma: a VA study

    Fillmore NR, Cirstea D, Munjuluri A, …, Szalat RE, Munshi NC

    Blood Advances5(18):3511-3514DOIPubMed

  5. Pathogenetic and Prognostic Implications of Increased Mitochondrial Content in Multiple Myeloma

    Ruiz-Heredia Y, Ortiz-Ruiz A, Samur MK, …, Szalat R, …, Gallardo M

    Cancers13(13):3189DOIPubMed

  6. Predictive factors of outcomes in patients with AL amyloidosis treated with daratumumab

    Szalat RE, Gustine J, Sloan JM, Edwards CV, Sanchorawala V

    American Journal of Hematology97(1):79-89DOIPubMed

2020

  1. Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group

    Samur MK, Aktas Samur A, Fulciniti M, Szalat R, …, Munshi NC

    Journal of Clinical Oncology38(27):3107-3118DOIPubMed

  2. Genomic Instability in Multiple Myeloma

    Alagpulinsa DA, Szalat RE, Poznansky MC, Shmookler Reis RJ

    Trends in Cancer6(10):858-873DOIPubMed

  3. Organ responses after highdose melphalan and stemcell transplantation in AL amyloidosis

    Szalat R, Sarosiek S, Havasi A, Brauneis D, Sloan JM, Sanchorawala V

    Leukemia35(3):916-919DOIPubMed

  4. Prevalence and Outcome of COVID-19 Infection in Cancer Patients: A National Veterans Affairs Study

    Fillmore NR, La J, Szalat RE, …, Munshi NC

    JNCI: Journal of the National Cancer Institute113(6):691-698DOIPubMed

2019

  1. Amplification and overexpression of E2 ubiquitin conjugase UBE2T promotes homologous recombination in multiple myeloma

    Alagpulinsa DA, Kumar S, Talluri S, …, Szalat R, …, Munshi NC

    Blood Advances3(23):3968-3972DOIPubMed

  2. Functional profiling of nucleotide Excision repair in breast cancer

    Rajkumar-Calkins AS, Szalat R, Dreze M, …, Mouw KW

    DNA Repair82:102697DOIPubMed

  3. Genomic landscape and chronological reconstruction of driver events in multiple myeloma

    Maura F, Bolli N, Angelopoulos N, …, Szalat R, …, Campbell PJ

    Nature Communications10(1)DOIPubMed

  4. Novel Agents in Multiple Myeloma

    Szalat R, Munshi NC

    The Cancer Journal25(1):45-53DOIPubMed

  5. Rôle des voies de réparation des dommages de l'ADN dans l'instabilité génomique observée au cours du myélome multipleThesis

    Szalat R

    Doctoral thesis, Université Sorbonne Paris CitéDOI

2018

  1. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

    Walker BA, Mavrommatis K, Wardell CP, …, Szalat R, …, Morgan G

    Leukemia33(1):159-170DOIPubMed

  2. Diagnosis of Castleman Disease

    Szalat R, Munshi NC

    Hematology/Oncology Clinics of North America32(1):53-64DOIPubMed

  3. Genomic patterns of progression in smoldering multiple myeloma

    Bolli N, Maura F, Minvielle S, …, Szalat R, …, Munshi N

    Nature Communications9(1)DOIPubMed

  4. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

    Walker BA, Mavrommatis K, Wardell CP, …, Szalat R, …, Morgan GJ

    Blood132(6):587-597DOIPubMed

  5. Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma

    Samur MK, Minvielle S, Gulla A, …, Szalat R, …, Munshi NC

    Leukemia32(12):2626-2635DOIPubMed

  6. Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma

    Fulciniti M, Lin CY, Samur MK, …, Szalat RE, …, Munshi NC

    Cell Reports25(13):3693-3705.e6DOIPubMed

2017

  1. Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines

    Maura F, Petljak M, Lionetti M, …, Szalat R, …, Bolli N

    Leukemia32(4):1043-1047DOIPubMed

  2. Expressed fusion gene landscape and its impact in multiple myeloma

    Cleynen A, Szalat R, Samur MK, …, Avet-Loiseau H

    Nature Communications8(1)DOIPubMed

  3. Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma

    Fulciniti M, Martinez-Lopez J, Senapedis W, …, Szalat R, …, Munshi NC

    Blood129(16):2233-2245DOIPubMed

  4. Non‐cirrhotic portal hypertension in necrobiotic xanthogranuloma associated with monoclonal gammopathy

    Vignon M, Placais L, Malphettes M, …, Szalat R, …, Arnulf B

    Journal of the European Academy of Dermatology and Venereology31(9)DOIPubMed

  5. Nucleotide excision repair is a potential therapeutic target in multiple myeloma

    Szalat R, Samur MK, Fulciniti M, …, Munshi NC

    Leukemia32(1):111-119DOIPubMed

  6. Understanding therapeutic emergencies in acute hemolysis

    Boutboul D, Touzot F, Szalat R

    Intensive Care Medicine44(4):482-485DOIPubMed

2016

  1. A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications

    Jakubikova J, Cholujova D, Hideshima T, …, Szalat RE, …, Anderson KC

    Oncotarget7(47):77326-77341DOIPubMed

  2. A rare case of disseminated skin and mucosal necrobiotic xanthogranuloma and xanthoma

    AlGain M, Szalat R, Vignon‐Pennamen MD, …, Bouaziz J‐

    Journal of the European Academy of Dermatology and Venereology31(1)DOIPubMed

  3. Catastrophic cryofibrinogenaemia associated with chronic lymphocytic leukaemia and salvage therapy using plasmapheresis and cyclophosphamide

    AlGain M, Damade R, Aucouturier F, …, Szalat R, …, Bouaziz JD

    Journal of the European Academy of Dermatology and Venereology31(1)DOIPubMed

  4. Corrigendum to “Genomic heterogeneity in multiple myeloma” [Curr. Opin. Genet. Dev. 30 (2015) 56–65]

    Szalat R, Munshi NC

    Current Opinion in Genetics & Development37:158DOIPubMed

  5. Gene Expression Profiles in Myeloma: Ready for the Real World?

    Szalat R, Avet-Loiseau H, Munshi NC

    Clinical Cancer Research22(22):5434-5442DOIPubMed

  6. Next-Generation Sequencing Informing Therapeutic Decisions and Personalized Approaches

    Szalat R, Munshi NC

    American Society of Clinical Oncology Educational Booke442-e448DOIPubMed

2015

  1. Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease

    Cohen C, Royer B, Javaugue V, Szalat R, …, Bridoux F

    Kidney International88(5):1135-1143DOIPubMed

  2. Genomic heterogeneity in multiple myeloma

    Szalat R, Munshi NC

    Current Opinion in Genetics & Development30:56-65DOIPubMed

  3. Good Syndrome: An Adult-Onset Immunodeficiency Remarkable for Its High Incidence of Invasive Infections and Autoimmune Complications

    Malphettes M, Gérard L, Galicier L, …, Szalat R, …, Oksenhendler E

    Clinical Infectious Diseases61(2):e13-e19DOIPubMed

  4. The spectrum of neutrophilic dermatoses associated with monoclonal gammopathy: Association with IgA isotype and inflammatory profile

    Szalat R, Monsel G, Le Goff W, …, Asli B

    Journal of the American Academy of Dermatology73(5):809-820DOIPubMed

2014

  1. Clinico‐biological characteristics and treatment of type I monoclonal cryoglobulinaemia: a study of 64 cases

    Harel S, Mohr M, Jahn I, …, Szalat R, …, Fermand J

    British Journal of Haematology168(5):671-678DOIPubMed

  2. Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation

    Fouquet G, Hebraud B, Garciaz S, …, Szalat R, …, Leleu X

    Journal of Cancer5(3):248-252DOIPubMed

  3. Physiopathology of necrobiotic xanthogranuloma with monoclonal gammopathy

    Szalat R, Pirault J, Fermand J‐, …, Goff WL

    Journal of Internal Medicine276(3):269-284DOIPubMed

2013

  1. Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma

    Leleu X, Fouquet G, Hebraud B, …, Szalat R, …, (IFM) OBOIFDM

    Leukemia27(11):2242-2244DOIPubMed

  2. Manifestations cutanées révélant une cryofibrinogénémie associée à une gammapathie monoclonale

    Delyon J, Bezier M, Cordoliani F, Malphettes M, Szalat R, Bagot M, Rybojad M

    Annales de Dermatologie et de Vénéréologie140(1):30-35DOIPubMed

2011

  1. Pathogenesis and treatment of xanthomatosis associated with monoclonal gammopathy

    Szalat R, Arnulf B, Karlin L, …, Fermand JP

    Blood118(14):3777-3784DOIPubMed

2010

  1. Anti-NuMA1 and anti-NuMA2 (anti-HsEg5) antibodies: Clinical and immunological features: A propos of 40 new cases and review of the literature

    Szalat R, Ghillani-Dalbin P, Jallouli M, Amoura Z, Musset L, Cacoub P, Sène D

    Autoimmunity Reviews9(10):652-656DOIPubMed

  2. Xanthomatoses et immunoglobuline monoclonale: à propos de 18 observations et revue de 233 cas de la littératureThesis

    Szalat R

    MD thesis, Département d'immunologie clinique, Hôpital Saint-Louis, Paris, France

Abstracts & posters 92

2026

  1. Non-random patterns of multiple primary malignancies in the era of cancer survival.

    George T, Nannini K, Bihn JR, Samur MK, Szalat RE, DuMontier C, Fillmore N, Munshi NC

    Journal of Clinical Oncology44(16_suppl):10584-10584DOI

  2. Performance Evaluation of a Novel Non-Invasive Monitoring Device for At-Home Neutropenia Detection in a Multicenter Cancer Cohort

    Srinivasan MD, Sloan JM, Wolf M, Ferri GM, Çetin O, Szalat RE, et al.

    Breast Cancer Research and Treatment 215 (1)

  3. Real-world one-year comparative outcomes of quadruplet and triplet induction regimens in older, transplant-ineligible multiple myeloma patients.

    Cetin O, Teker G, Szalat RE

    Journal of Clinical Oncology44(16_suppl):7567-7567DOI

2025

  1. Effect of duffy status on patients with breast cancer receiving cyclin-dependent kinase 4/6 inhibitors

    Ferri G, Beiner Martinez C, Acevedo J, Bhatt S, Verma K, Abdallah M, Szalat R, Sloan JM

    Blood146(Supplement 1):6170-6170DOI

  2. Single-cell transcriptomics of AL amyloidosis reveals pathogenic mechanisms, immune interactions and altered clonal and polyclonal plasma cell phenotypes

    Smith J, Samur M, Talluri S, …, Szalat R

    Blood146(Supplement 1):3923-3923DOI

2024

  1. Bone marrow plasma cells and immune microenvironment transcriptomic architecture in AL amyloidosis during daratumumab based therapy

    Szalat R, Talluri S, Wong S, Morgan G, Sanchorawala V, Munshi N, et al.

    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS31:S176-S176

  2. Clinical Characteristics and Therapeutic Response of Patients with Heavy Chain (AH) and Heavy and Light Chain (AHL) Amyloidosis

    Li KY, Staron A, Sanchorawala V, Szalat RE

    Blood144(Supplement 1):3303-3303DOI

  3. Clinical Characteristics and Treatment Outcomes of Patients with AL Amyloidosis with Acquired Factor X Deficiency

    Cetin O, Teodorescu P, Staron A, Sanchorawala V, Szalat RE

    Blood144(Supplement 1):4671-4671DOI

  4. Differentiating between MM like Smoldering Myeloma (SMM) and Non-Progressor SMM

    Aktas-Samur A, Fulciniti M, Shah P, …, Szalat RE, …, Munshi NC

    Blood144(Supplement 1):1018-1018DOI

  5. Disparities in Monoclonal Immunoglobulin-Associated Disorders in a Large and Diverse Cohort from a US Tertiary Safety-Net Center

    Aijaz A, Szalat RE

    Blood144(Supplement 1):6899-6899DOI

  6. Epidemiological Characteristics and Clinical Outcomes of Patients with Monoclonal Gammopathy of Renal Significance (MGRS) Diagnosed in a Large Safety-Net Hospital in the US

    Granina E, Henderson J, Bertrand KA, Sanchorawala V, Szalat RE

    Blood144(Supplement 1):4680-4680DOI

  7. Epidemiology and clinical characteristics of patients with monoclonal gammopathy of renal significance (MGRS) in a diverse population

    Granina E, Henderson J, Bertrand K, Sanchorawala V, Szalat R

    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS31:S135-S135

  8. Evaluation of Socioeconomic Barriers Impacting Patients with Newly Diagnosed Multiple Myeloma

    Srinivasan MD, Culnan J, Hora M, …, Szalat RE, …, Edwards CV

    Blood144(Supplement 1):5169-5169DOI

  9. Risk Factors for Suboptimal Treatment in Patients with Newly Diagnosed Multiple Myeloma across US Healthcare Systems

    Bodanapu G, Corrigan J, Culnan J, …, Szalat RE, …, Edwards CV

    Blood144(Supplement 1):3341-3341DOI

2023

  1. Composition and Dynamic Evolution of the Bone Marrow Microenvironment in AL Amyloidosis during Daratumumab Based Therapy

    Szalat RE, Talluri S, Royer CM, Wong S, Morgan G, Sanchorawala V, Samur MK, Munshi NC

    Blood142(Supplement 1):3416-3416DOI

  2. Hepatic Response and Progression Criteria in Light Chain Amyloidosis: A Multicenter Validation Study

    Muchtar E, Palladini G, Schonland S, …, Szalat RE, …, Gertz MA

    Blood142(Supplement 1):3411-3411DOI

  3. P-362 ID2 acts as a novel tumor suppressor in MM by inhibition of TCF3 transcriptional activity

    Perini T, Yao Y, Ng JF, …, Szalat R, …, Munshi N

    Clinical Lymphoma Myeloma and Leukemia23:S238-S239DOI

  4. Prospective Evaluation of Measurable Residual Disease (MRD) and Sustainability of the Response in Patients with Systemic AL Amyloidosis Treated with Daratumumab

    Staron A, Burks EJ, Szalat RE, Sanchorawala V

    Blood142(Supplement 1):3405-3405DOI

  5. When a Number Is Just a Number: Duffy-Null Blood Group Phenotype, Absolute Neutrophil Count, and Incidence of Neutropenic Fever and Chemotherapy Dose Reductions in Patients Treated for Plasma Cell Dyscrasias

    Abdallah M, Arters F, Patel J, …, Szalat RE

    Blood142(Supplement 1):7432-7432DOI

2022

  1. OAB-021: High-risk multiple myeloma due to extramedullary disease-like gene expression induced by bone marrow stromal cells

    Binder M, Szalat R, Fulciniti M, Avet-Loiseau H, Parmigiani G, Samur M, Munshi N

    Clinical Lymphoma Myeloma and Leukemia22:S13DOI

2021

  1. Chromatin Remodeling and Associated Changes in Gene Expression Induced By Bone Marrow Stromal Cells Identify Features of High-Risk Multiple Myeloma

    Binder M, Szalat RE, Fulciniti M, Parmigiani G, Samur MK, Munshi NC

    Blood138(Supplement 1):2672-2672DOI

  2. Defining Genomic Probability of Progression to Identify Low-Risk Smoldering Multiple Myeloma

    Aktas-Samur A, Fulciniti M, Derebail S, Szalat R, …, Munshi NC

    Blood138(Supplement 1):545-545DOI

  3. Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival

    Muchtar E, Dispenzieri A, Wisniowski B, …, Szalat R, …, Gertz MA

    Blood138(Supplement 1):2720-2720DOI

  4. Graded Renal Response Criteria for Light Chain (AL) Amyloidosis

    Muchtar E, Wisniowski B, Palladini G, …, Szalat R, …, Gertz MA

    Blood138(Supplement 1):2721-2721DOI

  5. OAB-036: Graded renal response criteria and revised renal progression criteria for light chain (AL) amyloidosis

    Muchtar E, Wisniowski B, Palladini G, …, Szalat R, …, Gertz M

    Clinical Lymphoma Myeloma and Leukemia21:S23-S24DOI

  6. OAB-043: Progression and probability of progression are driven by different genomic features in precursor conditions in myeloma

    Aktas-Samur A, Fulciniti M, Derebail S, Szalat R, …, Munshi NC

    Clinical Lymphoma Myeloma and Leukemia21:S28DOI

  7. Predictive Factors of Overall Survival in Patients with Relapsed AL Amyloidosis Treated with Single Agent Daratumumab

    Szalat R, Gustine J, Sloan JM, Sanchorawala V

    Blood138(Supplement 1):2734-2734DOI

  8. Presence of Extrachromosomal DNA (ecDNA) Impacts Both Progression Free and Overall Survival and Is an Independent Poor Prognostic Marker in Multiple Myeloma

    Shah P, Aktas-Samur A, Fulciniti M, Szalat R, …, Samur MK

    Blood138(Supplement 1):461-461DOI

  9. Transcriptional Deregulation Mediated By ID2-TCF3 Axis Supports MM Cell Growth and Proliferation in the Context of the Bone Marrow Milieu

    Yao Y, Perini T, Samur MK, Szalat R, Binder M, Anderson KC, Fulciniti M, Munshi NC

    Blood138(Supplement 1):2686-2686DOI

2020

  1. Genomic and Transcriptomic Characterization of IgM Multiple Myeloma Identifies a Pre-Germinal Center Plasma Cell Disorder with Immature B-Cell Transcription-Factor Signature

    Bazarbachi AH, Avet-Loiseau H, Hunter ZR, Szalat R, …, Munshi NC

    Blood136(Supplement 1):7-8DOI

  2. High Throughput Genomic Analysis Identifies Low-Risk Smoldering Multiple Myeloma

    Aktas-Samur A, Fulciniti M, Derebail S, Szalat R, …, Munshi NC

    Blood136(Supplement 1):2-2DOI

  3. High-Dose Melphalan Significantly Increases Mutational Burden in Multiple Myeloma Cells at Relapse: Results from a Randomized Study in Multiple Myeloma

    Samur MK, Roncador M, Aktas-Samur A, …, Szalat R, …, Munshi NC

    Blood136(Supplement 1):4-5DOI

2019

  1. Clinical Characteristics, Treatment Regimens and Survival in Elderly Patients with AL Amyloidosis in a Tertiary Referral Center

    Acevedo J, Doros G, Szalat R, Sloan JM, Sarosiek S, Sanchorawala V

    Blood134(Supplement_1):5447-5447DOI

  2. E2 ubiquitin conjugase UBE2T contributes to genome maintenance through homologous recombination in multiple myeloma

    Alagpulinsa D, Kumar S, Talluri S, …, Szalat R, …, Munshi N

    Clinical Lymphoma Myeloma and Leukemia19(10):e139DOI

  3. Favorable Progression-Free Survival Associated with Immune Bio-Markers Modulated By Pomalidomide in Relapsed/Refractory Multiple Myeloma: An Analysis of Phase III Study

    Prabhala R, Samur MK, Talluri S, …, Szalat R, …, Munshi NC

    Blood134(Supplement_1):1784-1784DOI

  4. Genome wide chromatin accessibility profiling identifies chromatin signatures and novel transcription factor dependencies in multiple myeloma

    Szalat R, Lawlor M, Fulciniti M, …, Munshi N

    Clinical Lymphoma Myeloma and Leukemia19(10):e8-e9DOI

  5. Inhibitor of DNA binding 2 (ID2) regulates key transcriptional programs in multiple myeloma

    Perini T, Szalat R, Samur M, …, Munshi N

    Clinical Lymphoma Myeloma and Leukemia19(10):e98-e99DOI

  6. Lack of Significant Differences in Somatic Alterations between MGUS, SMM and Symptomatic Multiple Myeloma: A Result from Comprehensive Genomic Profiling Study

    Aktas Samur A, Fulciniti M, Szalat R, …, Munshi NC

    Blood134(Supplement_1):3089-3089DOI

  7. PF588 SIGNIFICANT POM EFFECT ON THE IMMUNE‐CELL PROFILES IN B, T AND NK SUBSETS IN A LARGE COHORT CLINICAL TRIAL IN RELAPSED/REFRACTORY MYELOMA

    Prabhala R, Samur M, Talluri S, …, Szalat R, …, Munshi N

    HemaSphere3(S1):246DOI

  8. Recurrent somatic Alterations in the Non-Coding Genome Alter Gene Expression Levels and Correlate With Clinical Outcome

    Samur M, Samur A, Szalat R, …, Munshi N

    Clinical Lymphoma Myeloma and Leukemia19(10):e12-e13DOI

  9. S119 THE ROLE OF RECURRENT SOMATIC ALTERATIONS IN THE NON-CODING GENOME WITH FUNCTIONAL IMPLICATIONS IN MM

    Samur M, Szalat R, Aktas Samur A, …, Munshi N

    HemaSphere3(S1):11-12DOI

  10. S120 CHRONOLOGY OF COPY NUMBER ALTERATIONS FROM PRECURSORS TO MULTIPLE MYELOMA: WHAT COMES FIRST?

    Aktas Samur A, Minvielle S, Fulciniti M, Szalat R, …, Samur M

    HemaSphere3(S1):12DOI

  11. The Landscape of Genome Wide Somatic Alterations Identifies a Good-Risk Group in Newly Diagnosed Multiple Myeloma

    Samur MK, Aktas Samur A, Han T, …, Szalat R, …, Munshi NC

    Blood134(Supplement_1):3055-3055DOI

2018

  1. Analysis of mutations and structural variants to redefine the genomic landscape of multiple myeloma and its clinical implications

    Bolli N, Maura F, Dawson KJ, Angelopoulos N, Minvielle S, Martincorena I, et al.

    Haematologica103(S3):S51-S51

  2. Chromatin Accessibility Profiling Reveals Cis-Regulatory Heterogeneity and Novel Transcription Factor Dependencies in Multiple Myeloma

    Ott CJ, Szalat R, Lawlor M, …, Munshi N

    Blood132(Supplement 1):1313-1313DOI

  3. DNA repair processes target transcribed region in multiple myeloma

    Samur M, Szalat R, Lawlor M, Maura F, Ott C, Bolli N, Anderson K, et al.

    HEMASPHERE2(S1):211-211

  4. Dysregulated Translational Control Is a Central Feature of MM Mediated By 14-3-3ε Interactome Promoting Multiple Myeloma Cell Growth and Viability

    Xu Y, Fulciniti M, Ho M, …, Szalat R, …, Munshi N

    Blood132(Supplement 1):3176-3176DOI

  5. Inhibitor of DNA Binding 2 (ID2) Plays a Key Tumor Suppressor Role in Promoting Oncogenic Transformation in Multiple Myeloma

    Perini T, Szalat R, Samur MK, …, Munshi N

    Blood132(Supplement 1):60-60DOI

  6. Landscape of Recurrent Mutations in Non-Coding Genome with Functional Implications in Newly-Diagnosed Multiple Myeloma

    Samur MK, Chakraborty C, Szalat R, …, Munshi N

    Blood132(Supplement 1):190-190DOI

  7. The chronological order of copy number changes in hyperdiploid multiple myeloma patients

    Maura F, Bolli N, Dawson K, Angelopoulos N, Szalat R, Martincorena I, et al.

    HEMASPHERE2(S1):727-727

  8. The genomic landscape of structural variations and complex events in multiple myeloma

    Maura F, Dawson KJ, Angelopoulos N, Minvielle S, Martincorena I, et al.

    Haematologica103(S3):S14-S14

  9. The Landscape of Structural Variant Signatures in Multiple Myeloma Identifies Distinct Disease Subgroups with Implications for Pathogenesis

    Maura F, Leongamornlert D, Angelopoulos N, …, Szalat R, …, Bolli N

    Blood132(Supplement 1):109-109DOI

2017

  1. A NOVEL PREDICTIVE MODEL COMBINING LINCRNAS AND PROTEIN CODING GENES IN MULTIPLE MYELOMA

    Samur M, Gulla A, Fulciniti M, Szalat R, Samur AA, Shamas M, et al.

    HAEMATOLOGICA102:495-496

  2. Abnormalities in mitochondrial DNA copy number have pathogenetic and prognostic implications in multiple myeloma

    Ruiz-Heredia Y, Samur MK, Ortiz-Ruiz A, Fernández RA, et al.

    Blood, The Journal of the American Society of Hematology130(Suppl_1):4378 …

  3. Abstract 5719: Long intergenic non-coding RNAs: a new independent risk predictors in multiple myeloma

    Samur MK, Gulla A, Fulciniti M, …, Szalat R, …, Munshi N

    Cancer Research77(13_Supplement):5719-5719DOI

  4. Bone marrow microenvironment induces genomic instability and enables clonal evolution in multiple myeloma

    Perini T, Szalat R, Fulciniti M, Samur MK, Lopez MA, Nanjappa P, Wen K, et al.

    Blood130:4408

  5. Integrative Oncogenomic Analysis Combining Whole Genome, Transcriptome and Epigenome Identifies Altered Chromatin Accessibility Landscape in Multiple Myeloma

    Szalat R, Samur MK, Ott CJ, Lawlor M, Epstein C, Abraham BJ, Lin CY, et al.

    Blood130:328

  6. Mapping of the Multiple Myeloma Transcriptional Core Regulatory Circuitry Reveals TCF3 As a Novel Dependency and an Oncogenic Collaborator of MYC

    Lin CY, Fulciniti M, Lopez MA, …, Szalat R, …, Munshi N

    Blood130(Suppl_1):64-64DOI

  7. PAK4 Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldestrostom Macroglobulinemia

    Li N, Fulciniti M, Lopez MA, …, Szalat R, …, Munshi N

    Blood130(Suppl_1):648-648DOI

  8. Perturbation in B Cell-Subsets Can Explain the Observed Suppression of Uninvolved Immunoglobulins and Their Impact on T Tell-Subsets As Well As Patients Outcome in Myeloma

    Prabhala R, Acharya S, Stekla M, Talluri S, Szalat R, Nanjappa P, et al.

    Blood130:3049

  9. The apobec mutational activity in multiple myeloma: from diagnosis to cell lines

    Maura F, Petljak M, Minvielle S, Szalat R, Lionetti M, Cifola I, Liang W, et al.

    haematologica102(suppl. 3):124-124

  10. The genomic landscape of multiple myeloma complex structural variations

    Maura F, Bolli N, Dawson KJ, Angelopoulos N, Minvielle S, Martincorena I, et al.

    Blood, The Journal of the American Society of Hematology130(Suppl_1):330-330

  11. Ywhae Located on Chromosome 17p13 Promotes Myeloma Cells Proliferation Via Induction of Anti-Apoptosis and Survival Signaling Pathways

    Xu Y, Fulciniti M, Samur MK, Szalat R, Ho M, Lopez MA, Li N, Lin J, et al.

    Blood, The Journal of the American Society of Hematology130(Suppl_1):1755 …

2016

  1. A Detailed Alternate Splicing Landscape in Multiple Myeloma with Significant Potential Biological and Clinical Implications

    Aktas Samur A, Samur MK, Minvielle S, …, Szalat R, …, Munshi NC

    Blood128(22):356-356DOI

  2. A targeted sequencing approach in multiple myeloma reveals a complex landscape of genomic lesions that has implications for prognosis

    Bolli N, Biancon G, Gimondi S, Li Y, Sathiaseelan V, Maura F, Carniti C, et al.

    HAEMATOLOGICA101(Suppl. 1):160-160

  3. Analysis of Mutational Signatures Suggest That Aid Has an Early and Driver Role in Multiple Myeloma

    Maura F, Bolli N, Minvielle S, …, Szalat R, …, Munshi N

    Blood128(22):116-116DOI

  4. Global Genomic Analysis of Newly Diagnosed t(4 ;14) Multiple Myeloma Reveals a Specific Mutational Spectrum and Identifies PKD2 As a Potential Therapeutic Target

    Song XL, Szalat R, Talbot A, …, Bories JC

    Blood128(22):4462-4462DOI

  5. IMPORTANCE OF SERINE/THREONINE KINASE PAK4 IN MULTIPLE MYELOMA: THERAPEUTIC APPLICATIONS OF A NEW CLASS OF INHIBITORS

    Joaquin ML, Mariateresa F, Maria L, Stefania O, Rajya LB, Annamaria G, et al.

    HAEMATOLOGICA101:21-21

  6. p21-Associated Kinase 4 (PAK4) Addiction in Multiple Myeloma: A Potential Therapeutic Application with Enhanced Activity in FGFR3 Expressing Myeloma

    Fulciniti M, Martinez Lopez J, Senapedis W, …, Szalat R, …, Munshi NC

    Blood128(22):3302-3302DOI

  7. The Complex Landscape of Rearrangements in Smoldering and Symptomatic Multiple Myeloma Revealed By Whole-Genome Sequencing

    Szalat R, Bolli N, Maura F, …, Munshi NC

    Blood128(22):236-236DOI

  8. Whole Genome Sequencing of Unique Paired SMM/MGUS Progressing to MM Samples Reveals a Genomic Landscape with Diverse Evolutionary Pattern

    Bolli N, Maura F, Minvielle S, …, Szalat R, …, Munshi N

    Blood128(22):2088-2088DOI

2015

  1. Dysregulated Nucleotide Excision Repair (NER) Is a New Target in Multiple Myeloma

    Szalat R, Samur MK, Cleynen A, …, Munshi NC

    Blood126(23):4187-4187DOI

  2. Étude nationale observationnelle des cutis laxa associées à une gammapathie monoclonale

    Saussine A, Bouaziz JD, Asli B, …, Szalat R, …, Rybojad M

    Annales de Dermatologie et de Vénéréologie142(12):S482-S483DOI

  3. Measurement of nucleotide excision repair activity and correlation with cisplatin sensitivity.

    Calkins A, Szalat R, Dreze M, Schnorenberg M, Ceccaldi R, Iglehart JD, Lazaro JB

    Journal of Clinical Oncology33(15_suppl):1077-1077DOI

  4. The Fusion Gene Landscape in Multiple Myeloma, with Clinical Impact

    Cleynen A, Szalat R, Samur MK, Parmigiani G, Munshi NC, Avet-Loiseau H

    Blood126(23):835-835DOI

2014

  1. Efficacité du bortézomib dans la maladie de dépôts d’immunoglobuline monoclonale de type Randall

    Cohen C, Caulier A, Royer B, …, Szalat R, …, Bridoux F

    Néphrologie & Thérapeutique10(5):273DOI

  2. Frequent Igh Fusion Transcripts with Clinical Impact in Multiple Myeloma

    Cleynen A, Szalat R, Samur MK, Rashid N, Parmigiani G, Munshi NC, Avet-Loiseau H

    Blood124(21):721-721DOI

  3. Nucleotide Excision Repair (NER) Is Frequently Impaired and Affects Outcome in Multiple Myeloma (MM)

    Szalat R, Dreze M, Samur MK, …, Munshi NC

    Blood124(21):2055-2055DOI

2013

  1. Clinical and Biological Features Of Multiple Myeloma (MM) and Monoclonal Gammopathies In Patients With Human Immunodeficiency Virus (HIV) Infection

    Talbot A, Gérard L, Szalat R, …, Arnulf B

    Blood122(21):5348-5348DOI

  2. Consolidation with VTd Improves the CR Rate Following VTd Induction and Single Autotransplantation in Multiple Myeloma: P-137

    XAVIER L, LELEU X, FOUQUET G, HEBRAUD B, ROUSSEL M, et al.

    Clinical Lymphoma, Myeloma & Leukemia13:s108-s109

  3. CONSOLIDATION WITH VTD SIGNIFICANTLY IMPROVES THE COMPLETE REMISSION RATE IN MULTIPLE MYELOMA

    Leleu X, Fouquet G, Hebraud B, Roussel M, Caillot D, Chretien ML, et al.

    HAEMATOLOGICA98:100-100

  4. Dermatoses neutrophiliques et gammapathies monoclonales : 26 cas et revue de la littérature

    Monsel G, Szalat R, Battistella M, Vignon-Pennamen MD, Bagot M, Fermand JP, Asli B, Rybojad M

    Annales de Dermatologie et de Vénéréologie140(12):S605DOI

  5. Échec des anti-IL1 (anakinra) dans un syndrome de Schnitzler variant IgG

    Hau E, Asli B, Rivet J, …, Szalat R, …, Bouaziz JD

    Annales de Dermatologie et de Vénéréologie140(12):S599-S600DOI

  6. IgM Hevylite Assay as a Biomarker of Clinical Outcome in Patients with Anti-MAG Neuropathy: P-457

    ARNULF B, BENGOUFA D, LAZARETH A, SZALAT R, MALPHETTES M, et al.

    Clinical Lymphoma, Myeloma & Leukemia13:s254-s255

  7. Impact Of Consolidation With Bortezomib-Thalidomide-Dexamethasone (VTd) Upfront In Multiple Myeloma (MM) With Partial Response (PR) At Completion Of Induction With Vtd

    Leleu X, Fouquet G, Hebraud B, …, Szalat R, …, Moreau P

    Blood122(21):3221-3221DOI

  8. Xanthogranulome nécrobiotique et myélome multiple

    Elfatoiki FZ, Shneider P, Szalat R, Bagot M

    Annales de Dermatologie et de Vénéréologie140:S103DOI

2012

  1. Consolidation with Vtd Significantly Improves the Complete Remission (CR) Rate Following Vtd Induction and Single Autologous Stem Cell Transplantation (auto) in Multiple Myeloma (MM).

    Leleu X, Hebraud B, Fouquet G, …, Szalat R, …, Moreau P

    Blood120(21):3096-3096DOI

  2. Impact of Tandem Autologous/Non Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma Relapsing After a First High Dose Therapy in the Era of Novels Anti-Myeloma Agents

    Harel S, Bernard S, Chevret S, …, Szalat R, …, Socie G

    Blood120(21):2035-2035DOI

  3. Prognostic Value of the Different MMSET Gene Breakpoints and Correlation with Immunoglobulin Isotype and FGFR3 Expression in 173 Patients with t(4;14) Multiple Myeloma

    Arnulf B, Lazareth A, Soulier J, …, Szalat R, …, Fermand JP

    Blood120(21):3971-3971DOI

2011

  1. Total Body Irradiation (TBI) or Busulfan (Bu) Plus High Dose Melphalan After Bortezomib (Bz) Containing Regimen As Front Line Treatment of High Risk Multiple Myeloma (MM) Patients with 17p Deletion and/or t(4;14) Translocation

    Arnulf B, Szalat R, Karlin L, Harel S, Asli B, Malphettes M, Soulier J, Fermand JP

    Blood118(21):4501-4501DOI

2008

  1. Anticorps anti-NuMA (Anti-Nuclear Mitotic Apparitus) : corrélation clinique et immunologique à partir de 14 cas et revue de la littérature

    Szalat R, Sène D, Ghillani-Dalbin P, Jallaoui M, Musset L, Cacoub P

    La Revue de Médecine Interne29:S314DOI

  2. Manifestations pulmonaires au cours du syndrome de Gougerot-Sjögren (SGS) à partir d’une série monocentrique de 108 patients

    Jallouli M, Sène D, Amoura Z, Szalat R, Costedoat-Chalumeau N, Trad S, Piette JC, Cacoub P

    La Revue de Médecine Interne29:S317-S318DOI